Sinaptica Therapeutics raises €25M Series B ahead of Alzheimer's TMS Phase 2 initiation
Summary
Genoa-based Sinaptica Therapeutics secured €25M Series B led by EQT Life Sciences, with Sofinnova Partners and new investor LSP, ahead of initiating their Phase 2 trial of connectome-guided personalized TMS for Alzheimer's disease across 6 Italian and German centers. The round also funds manufacturing scale-up of their integrated neuronavigation-TMS system.
Why it matters
EQT Life Sciences entering Sinaptica at Series B is a major validation — EQT focuses on late clinical and commercial European biotech and rarely invests at Phase 2 initiation without high conviction in the data and team. Sinaptica's Phase 2 initiation with top-tier European neurodegenerative VCs backing it makes this one to watch closely.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial